Daniel Allen Gold Sells 425,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 425,000 shares of the stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $26.67, for a total transaction of $11,334,750.00. Following the transaction, the director owned 15,928,113 shares of the company’s stock, valued at $424,802,773.71. This represents a 2.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Daniel Allen Gold also recently made the following trade(s):

• On Friday, February 13th, Daniel Allen Gold sold 375,784 shares of Roivant Sciences stock. The stock was sold at an average price of $26.50, for a total transaction of $9,958,276.00.
• On Wednesday, December 17th, Daniel Allen Gold sold 777,332 shares of Roivant Sciences stock. The stock was sold at an average price of $23.07, for a total value of $17,933,049.24.
• On Tuesday, December 16th, Daniel Allen Gold sold 917,282 shares of Roivant Sciences stock. The shares were sold at an average price of $23.04, for a total value of $21,134,177.28.
• On Wednesday, November 19th, Daniel Allen Gold sold 1,300,000 shares of Roivant Sciences stock. The stock was sold at an average price of $20.23, for a total transaction of $26,299,000.00.

Roivant Sciences Stock Down 1.1%

NASDAQ ROIV opened at $26.45 on Friday. The stock’s 50-day simple moving average is $22.71 and its two-hundred day simple moving average is $18.36. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $27.94. The company has a market capitalization of $18.40 billion, a price-to-earnings ratio of -22.61 and a beta of 1.22.

Hedge Funds Weigh In On Roivant Sciences

A number of hedge funds have recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. boosted its position in shares of Roivant Sciences by 1,740.3% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after buying an additional 1,166 shares during the last quarter. Jones Financial Companies Lllp grew its stake in shares of Roivant Sciences by 226.0% in the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock worth $25,000 after acquiring an additional 1,148 shares during the period. Allworth Financial LP raised its holdings in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares during the last quarter. Bessemer Group Inc. raised its holdings in shares of Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the last quarter. Finally, Kestra Advisory Services LLC bought a new position in Roivant Sciences during the fourth quarter valued at approximately $47,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Key Roivant Sciences News

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Multiple analysts raised price targets and maintained bullish ratings (HC Wainwright, Goldman Sachs, Leerink, Citi — consensus PT ~ $28.69), supporting a positive headline narrative for the stock. MarketBeat ROIV coverage
• Positive Sentiment: Institutional flows show new and increased positions (several funds added ROIV, LPL Financial materially increased its stake), which can provide demand support below recent highs. MarketBeat institutional ownership report
• Neutral Sentiment: HC Wainwright slightly improved its FY2026 EPS view (less negative) and kept a Buy rating with a $33 target — this is mixed for stock moves because estimates remain negative even as the price target was raised. HC Wainwright note
• Negative Sentiment: Director Daniel Allen Gold sold two large blocks (425,000 shares on Feb 11 and 375,784 shares on Feb 13) at ~ $26.50 per share (SEC filing). Large director sales can create near‑term selling pressure and raise investor caution. SEC filing — Daniel Gold sales
• Negative Sentiment: Insider Mayukh Sukhatme sold 339,441 shares on Feb 9 at ~$26.47; this is another sizable insider disposition following previous large sales, which may weigh on sentiment. InsiderTrades / sale report
• Negative Sentiment: HC Wainwright cut several 2027 quarterly EPS forecasts and lowered FY2027 EPS materially (from about -$1.22 to -$1.79), signaling expectations for weaker near‑term financial performance — a clear negative for sentiment until operational catalysts emerge. HC Wainwright estimate update

Analysts Set New Price Targets

Several analysts recently weighed in on ROIV shares. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a report on Saturday, February 7th. Leerink Partners lifted their target price on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Guggenheim increased their price target on shares of Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. The Goldman Sachs Group raised their price objective on shares of Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Finally, HC Wainwright lifted their price objective on Roivant Sciences from $26.00 to $33.00 and gave the company a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $28.69.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.